Tempus ECG-AF vs RX-1 Rhythm Express Remote Cardiac Monitoring System

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Tempus ECG-AF

by Tempus AI, Inc.

RX-1 Rhythm Express Remote Cardiac Monitoring System

by VivaQuant, Inc.

AI Verdict

Tempus ECG-AF is an AI-based software that analyzes existing 12-lead ECGs to predict the risk of developing atrial fibrillation in patients aged 65 or older within the next 12 months. In contrast, the RX-1 Rhythm Express Remote Cardiac Monitoring System is a wearable device providing continuous ECG monitoring for the real-time detection and diagnosis of existing arrhythmias. While both leverage AI in cardiology, they address different stages of patient care: one for predictive risk assessment and the other for active diagnostic monitoring.

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary objective is proactive risk stratification for new-onset atrial fibrillation in an elderly, asymptomatic population. This AI-based algorithm is ideal for identifying patients aged 65 or older at increased risk of developing AF within the next 12 months, leveraging standard 12-lead ECGs to support earlier identification and follow-up.

View Tempus ECG-AF →

Choose RX-1 Rhythm Express Remote Cardiac Monitoring System if…

Choose the RX-1 Rhythm Express Remote Cardiac Monitoring System if you require continuous, long-term diagnostic monitoring for suspected or intermittent arrhythmias. This wearable patch device is best suited for patients experiencing symptoms or needing extended observation, offering Holter, Event, and Mobile Cardiac Telemetry modes with near real-time data transmission for comprehensive arrhythmia detection.

View RX-1 Rhythm Express Remote Cardiac Monitoring System →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Tempus ECG-AF	RX-1 Rhythm Express Remote Cardiac Monitoring System
Pricing	Contact vendor	Available
Deployment	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.	Cloud-based
BAA Available	Yes AI-estimated	Unknown
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tempus ECG-AF

Tempus ECG-AF integrates directly into existing healthcare facility systems and analyzes standard 12-lead ECGs, requiring no new patient-facing hardware or patient compliance for device wear. This seamless integration into current clinical workflows likely results in higher overall usability for healthcare providers, as it leverages existing infrastructure.

Clinical Value

Tempus ECG-AF

Tempus ECG-AF offers a unique predictive capability, identifying patients 65 or older at increased risk of developing Atrial Fibrillation within 12 months from a standard ECG. This proactive approach enables earlier identification and follow-up, potentially reducing AF-related strokes. While RX-1 Rhythm Express provides excellent continuous diagnostic monitoring, the predictive nature of Tempus ECG-AF represents a more advanced and potentially impactful application of AI in preventative cardiology.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF provides clear CMS reimbursement information with specific CPT codes (0764T and 0765T) and a Medicare rate of $128.90, effective January 1, 2025, offering a highly transparent and predictable financial pathway for healthcare providers. It also offers a transparent self-pay price of $295 for patients. While RX-1 Rhythm Express offers flexible pricing models, the concrete reimbursement details for Tempus ECG-AF provide a more immediate and measurable understanding of its financial value.

Enterprise Readiness

Tempus ECG-AF

Tempus ECG-AF is designed as a software solution that integrates into existing healthcare facility systems and is compatible with major ECG vendors like GE Medical Systems and Philips Medical Systems. This approach, along with EHR integrations, allows for smoother and more scalable deployment within large enterprise environments. While Tool B is also enterprise-ready with EHR interfacing, managing a fleet of patient-worn devices can introduce additional logistical complexities.

Innovation

Tempus ECG-AF

Tempus ECG-AF's innovative application of AI to predict the *future risk* of Atrial Fibrillation from a standard 12-lead ECG represents a significant shift towards proactive and preventative cardiac care. This predictive capability, enabling earlier identification and potential intervention, is a more groundbreaking innovation compared to the advancements in continuous monitoring offered by Tool B, however impressive its signal processing and wearable design.

Support & Docs

RX-1 Rhythm Express Remote Cardiac Monitoring System

VivaQuant's RX-1 Rhythm Express provides comprehensive and explicit support, including 24/7/365 phone and email support for both patients and providers, along with dedicated 'Use Manual,' 'Clinician's User Manual,' and 'Patient Use Guide' with troubleshooting information. This level of detailed and accessible support documentation is more clearly articulated and readily available than what is provided for Tempus ECG-AF.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Tempus ECG-AF	RX-1 Rhythm Express Remote Cardiac Monitoring System
Tool Name	Tempus ECG-AF	RX-1 Rhythm Express Remote Cardiac Monitoring System
Company	Tempus AI, Inc.	VivaQuant
Description	FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.	FDA-cleared, patch-style wearable device offering continuous ECG monitoring in MCT, Event, and Holter modes. It utilizes proprietary MDSPu2122 technology for superior noise suppression and accurate arrhythmia detection, providing near real-time data transmission to a cloud platform for physician review.
Key Functionality	AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.	Proprietary Multi-Domain Signal Processing (MDSPu2122) technology for noise suppression; AI-enabled advanced signal processing for arrhythmia detection; Continuous 2-channel ECG monitoring; Mobile Cardiac Telemetry (MCT), Event Recorder (ER), and Wireless Holter (WH) modes.
Target Patient Population	Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.	Not specified

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-AF and RX-1 Rhythm Express Remote Cardiac Monitoring System.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What is the primary clinical application difference between these two tools?

Tempus ECG-AF is an AI-based algorithm that analyzes 12-lead ECGs to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. In contrast, the RX-1 Rhythm Express Remote Cardiac Monitoring System is a patch-style wearable device offering continuous 2-channel ECG monitoring in Mobile Cardiac Telemetry (MCT), Event, and Holter modes for arrhythmia detection and physician review.

How do the data acquisition methods differ for these tools?

Tempus ECG-AF analyzes existing FDA authorized resting 12-lead ECG recordings from compatible systems such as GE Medical Systems and Philips Medical Systems. The RX-1 Rhythm Express system, on the other hand, uses a patch-style wearable device to collect continuous 2-channel ECG data directly from the patient.

What are the specific patient populations or conditions for which each tool is intended?

Tempus ECG-AF is intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, to assess their risk of developing AF within 12 months. The RX-1 Rhythm Express is intended for patients greater than 10 kg who have or are at risk of cardiac disease and those with intermittent symptoms requiring continuous cardiac monitoring.

How do these tools integrate into a clinical workflow?

Tempus ECG-AF is a software solution integrated into healthcare facility systems with advanced cardiology algorithms, designed to work with existing ECG platforms and EHRs. The RX-1 Rhythm Express involves a wearable device for patients that transmits data via built-in cellular connectivity to a cloud-based platform for data management and physician review.

What are the differences in their reimbursement or pricing models?

Tempus ECG-AF has CMS reimbursement available, with CPT codes 0764T and 0765T assigned to APC 5734, and a Medicare rate of $128.90, effective January 1, 2025. The RX-1 Rhythm Express offers flexible pricing via subscription, fee-for-service, or split-bill models.

What types of ECG data do these tools analyze?

Tempus ECG-AF analyzes 12-lead resting ECG recordings. The RX-1 Rhythm Express provides continuous 2-channel ECG monitoring.

What is the nature of the AI/signal processing capabilities in each tool?

Tempus ECG-AF utilizes an AI-based algorithm trained on over 1.5 million ECGs from over 500,000 patients to detect signs associated with new onset Atrial Fibrillation (AF) within 12 months. The RX-1 Rhythm Express employs proprietary Multi-Domain Signal Processing (MDSPu2122) technology for superior noise suppression and AI-enabled advanced signal processing for arrhythmia detection.